Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Respiratory and Pulmonary System

Categories

[Search within category]

METHOD FOR DETECTING AND TREATING NASAL AND LUNG DYSBIOSIS PATIENTS WITH MICROORGANISMS

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

NOVEL SMALL MOLECULE COMPOUNDS AND TARGET FOR TREATMENT OF AIRWAY HYPERRESPONSIVENESS IN ASTHMA

Novel small molecule compounds that modulate a new target for the treatment of asthma. 

Lineage-Negative Progenitor Cells Mobilize To Regenerate Lung Epithelium After Major Injury

This invention is a novel method of isolating a rare lineage-negative epithelial progenitor (LNEP) cell population and introducing it into the lungs of patients suffering from chronic fibrosis or acute injury.

Epithelial Growth Factor Receptor Antagonists Prevent Airway Mucus Production

This invention identifies a novel use for epidermal growth factor receptor (EGFR)antagonists in the treatment of airway mucus hypersecretion in patients, and includes invitro and in vivo screening assays.

Compositions And Methods For Treating And Diagnosing Asthma

To date, genome-wide expression analyses have not identified genetic biomarkers that are prognostic or predictive of therapeutic response to treatment for individual asthma patients, nor have they identified genetic biomarkers that distinguish subtypes of asthmatic patients.  In addition, no reliable non-genetic biomarkers with broad clinical applicability for prognostic or predictive responses to therapeutic treatment, or diagnostic of subtypes of asthma, have been identified.  Thus, as asthma patients seek treatment, there is considerable trial and error involved in the search for therapeutic agent(s) effective for a particular patient.  Such trial and error often involves considerable risk and discomfort to the patient in order to find the most effective therapy. Thus, there is a need for more effective means for determining which patients will respond to which treatment and for incorporating such determinations into more effective treatment regimens for asthma patients.

NOVEL MUCOLYTIC COMPOUNDS FOR TREATMENT OF PATHOLOGIC MUCUS IN AIRWAY DISEASES.

The incidence and complications arising from airway diseases are constantly increasing and chronic conditions of the airway significantly outnumber those of diabetes, cancer, heart disease combined. A quarter of the U.S. population are affected by airway diseases such as acute and chronic bronchitis, pneumonia, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, bronchiolitis, ventilator-associated airway mucus hyper-secretion, and acute and chronic sinusitis. Mucus overproduction and hypersecretion have been implicated to play a key role in these airway diseases.  However, mucus pathology is very poorly understood and hence recent advances have not been sufficient to develop effective treatments. Existing mucolytic drugs provide only moderate relief and have a number of limitations such as weak potency, volatility, bad smell in addition to side effects such as nausea, rash and sores. There is a need to address the large unmet need for novel mucolytic therapies for a wide range of acute and chronic airway disease.

Integrin Avb8 Neutralizing Antibody

Brief description not available

  • Go to Page: